China cross-border M&A opportunities

China cross-border M&A opportunities

The Webinar will be the first of our M&A WORLDWIDE Webinars of 2023 in collaboration with our members.

As a kick-off, we have invited ARC Group, our exclusive member in China, a leading China-based investment bank, to bridge several cross-border M&A opportunities related to China.

The following topics will the discussed in the Webinar.
•   ARC & MAWW Introduction
•   Economics Snapshot of China
•   China – a changing landscape
•   China post covid-19
•   Cross-border M&A Overview
•   Opportunities and challenges
•   Closing remarks.

All eyes are on China after the recent lifting of covid-19 restrictions. ARC Group is pleased to share insights from this important region at a crucial time.

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission